Back to Search
Start Over
A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
- Source :
-
Leukemia & Lymphoma . Apr2015, Vol. 56 Issue 4, p1043-1049. 7p. - Publication Year :
- 2015
-
Abstract
- Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles. Twenty-three patients with lymphoma were treated. Ten patients completed the full 11 -cycle treatment plan per protocol, four patients were removed due to progressive disease and seven withdrew or were removed from the study due to toxicities. Despite Prevnar vaccine administration every 2 months for three injections, the mean antibody concentration never reached protective levels (>0.35 pg/mL). Fatigue and functional well-being measured by Brief Fatigue Inventory and Functional Assessment of Cancer Therapy-General improved significantly from cycle 1 to cycle 7, but depression scores from the Center for Epidemiologic Studies Depression scale did not change. Given the toxicities observed, this broad-spectrum deacetylase inhibitor at this schedule is not optimal for prolonged maintenance therapy. [ABSTRACT FROM AUTHOR]
- Subjects :
- *LYMPHOMAS
*AUTOGRAFTS
*CANCER treatment
*VACCINES
*DEACETYLASES
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 56
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 102367274
- Full Text :
- https://doi.org/10.3109/10428194.2014.963073